Introduction
============

In 2017, it is predicted that 63,990 patients will be diagnosed with kidney cancer in the USA and 14,400 inpatients will die [@B1]. Renal cell carcinoma (RCC) is the predominant form of kidney cancer, accounting for 2-3% of all adult malignancies [@B2]. Clear cell RCC (ccRCC) is the most common (75%) and most lethal subtype of RCC [@B3]. Although recent surgical developments have improved the overall survival of patients with ccRCC, the long-term prognosis remains unsatisfactory. Therefore, there is an urgent need for a better understanding of the molecular mechanisms underlying ccRCC development.

In recent years, deregulated protein synthesis and degradation have been shown to contribute to cancer development and progression [@B4], [@B5]. Translation initiation is the critical rate-limiting process in the synthesis of most proteins [@B6]. Research has shown that inhibition of eukaryotic translation initiation factors (eIFs) is key in terms of reducing tumor initiation and progression, and improving prognosis; eIFs are promising therapeutic targets [@B4], [@B5].

Of the 12 known eIFs, the multi-subunit complex known as eukaryotic translation initiation factor 3 (eIF3) is the largest, with 13 putative subunits [@B7]. Of the 13 subunits, eIF3b forms a central core to which the other components bind with varying affinities [@B6], [@B8]. After binding to the 40S ribosomal subunit [@B9], eIF3 serves as a platform that recruits other protein components to form the 43S pre-initiation complex [@B10]. Furthermore, eIF3b interacts with eIF4G, resulting in formation of the 48S pre-initiation complex, which recognizes the AUG start codon [@B11]. The contribution made by the eIF3 subunits eIf3a, eIf3b, eIF3c, eIF3e, eIF3h, eIF3i, and eIF3m to malignant transformation and progression have been defined over the past few years [@B12]-[@B17]. These factors are potentially prognostic biomarkers of several types of cancer, are easy to measure, and may form the basis of a new class of cancer therapeutics. Within the eIF3 complex, subunit b (eIF3b) is a major scaffold protein with which the other core subunits interact [@B18].

Earlier research showed that eIF3b played an important role in colon cancer [@B13], glioblastoma [@B12], esophageal squamous carcinoma [@B19], and bladder cancer [@B20]. However, the role of eIF3b in ccRCC remains unclear. In the present study, we show that eIF3b is both a promising prognostic biomarker and a potential therapeutic target in patients with ccRCC.

Materials and Methods
=====================

Patients and specimens
----------------------

A total of 82 cancer specimens and tumor-adjacent renal tissues were obtained from patients with pathologically confirmed ccRCC who underwent radical or partial nephrectomy in 2009 or 2010 at the Department of Urology, Shandong University Qilu Hospital, Jinan, China. No patient underwent preoperative radiotherapy, chemotherapy, or immunotherapy. All specimens were re-evaluated using the TNM staging system [@B21]; the nuclear grades were scored using the Fuhrman criteria [@B22]. Patients with incomplete follow-up records were excluded. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed on random tissue samples obtained during radical, partial, or cytoreductive nephrectomy; the tissues were stored in liquid nitrogen prior to use. The samples included 27 normal kidney (NK) tissues taken \>2 cm distant from tumors; 30 adjacent NK tissues (ANKs) taken \<1 cm distant from tumors; 25 non-metastatic tumor tissues; 5 pairs of primary tumor tissues and metastatic tumor tissues obtained from patients with metastatic ccRCC. Written informed consent was obtained from all patients. Our study was approved by the Ethics Board of Qilu Hospital and was performed in accordance with all relevant principles of the Declaration of Helsinki.

Cell culture
------------

All cell lines were obtained from the American Type Culture Collection (ATCC, USA). A498 human kidney cancer cells were cultured in Eagle\'s Minimum Essential Medium (ATCC, USA) with 10% (v/v) fetal bovine serum (FBS). KRC-Y and 786-o human kidney cancer cells, and HK-2 proximal tubular cells, were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Hyclone, USA) with 10% (v/v) FBS. CAKI-1 and CAKI-2 kidney cancer cells were cultured in McCoy\'s Modified 5a Medium (Gibco, USA) with 10% (v/v) FBS. All cells were incubated at 37°C under 5% (v/v) CO2.

Small interfering RNA (siRNA) transfection
------------------------------------------

SiRNA was transfected with the aid of Lipofectamine® RNAiMAX (catalog no.13778-150; Invitrogen, USA) according to the manufacturer\'s instructions. The siRNA targeting eIF3b (designed by Invitrogen, USA) was 5′- GUCCAAAGCCUCAAAGGAAdTdT-3′. We also used a negative control siRNA.

RNA preparation and reverse transcription PCR
---------------------------------------------

Total RNA was extracted from frozen tissues and cells using an RNeasy® Mini Kit (catalog no. 74104; Qiagen, USA). cDNA was synthesized from 2-µg amounts of total RNA using a ReverTra Ace® qPCR RT Kit (catalog no. FSQ-101; Toyobo, Japan) according to the manufacturer\'s instructions. All cDNA was stored at -20°C prior to analysis.

qRT-PCR
-------

Primers were synthesized by Biosune (Jinan, China). EIF3b expression levels were quantified using a LightCycler® 2.0 (Roche, USA); we employed the R = 2^-ΔΔCT^ method. All experiments were performed in triplicate and the data were presented as means ± standard deviation (SD). PCR was performed with the aid of the SYBR® Green Real-Time PCR Master Mix (catalog no. QPK-201; Toyobo, Japan). The primers were: eIF3b forward: 5′-CGGTGCCTTAGCGTTTGTG-3′; reverse: 5′-CGGTCCTTGTTGTTCTTCTGC-3′; α-tubulin forward: 5′-CATGTACGTTGCTATCCAGGC-3′; reverse: 5′-CTCCTTAATGTCACGCACGAT-3′.

Western blotting
----------------

For Western blotting, siRNA-transfected cells were harvested after 72 h of culture into RIPA Lysis Buffer (Beyotime, China) and PMSF (Phenylmethanesulfonyl fluoride, Beyotime) at a 100:1 (v/w) ratio. Protein concentrations were measured using a BCA Protein Quantitative Kit (DBI Bioscience, Germany). We used an anti-eIF3B antibody (catalog no. ab124778; Abcam, USA).

Immunohistochemistry and immunofluorescence
-------------------------------------------

FFPE (Formalin Fixed and Paraffin Embedded) samples were retrieved from the Department of Pathology of Qillu hospital and cut into 5-µm-thick sections. Final staining scores were determined by the staining intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining) and the percentage of positive cells (scored 0, 0-10%; 1, 10-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%). The final staining score was the sum of the staining intensity and the percentage of positive cells, and was further graded as follows: 0-1, (-); 2-3, (+); 4-5, (++); and 6-7, (+++) (Figure [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B). On this basis, the tumor eIF3b expression level was rated as either negative (-) or positive (+, ++, or +++). The expression of eIF3b in ANK tissue was graded as low (+ and ++) or high (+++). Nuclear status was graded by three observers using the Fuhrman system. For immunofluorescence measurements, cells were cultured on chambered slides for 72 h after siRNA transfection and an anti-eIF3B antibody (catalog no. sc-271539; Santa Cruz Biochemicals, USA) was added. Images were acquired using an Olympus IX81 microscope (Olympus, Japan).

Cell counting kit 8 (CCK-8) assay and cell proliferation
--------------------------------------------------------

To prepare standard curves, A498 and CAKI-2 cells were seeded into 96-well plates at cell densities of 1000, 2000, 4000, 6000, 8000, and 10000 per well. Optical densities (ODs) at 450 nm were read with the aid of a Varioskan Flash (Thermo Scientific, Finland) after incubation at 37°C for 1.5 h with 2-(4-indophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2-tetrazolium monosodium salt (the CCK-8 reagent; Bestbio, China). Next, logarithmically growing siRNA-transfected cells were seeded into 96-well plates at 2,300 and 1,200 cells/well, respectively, and incubated for 0, 8, 16, 24, 32, 40, 48, 56, 64 and 72 h. At various times, samples were taken and incubated with the CCK-8 reagent for 1.5 h at 37°C and the ODs were measured. The averages of the values obtained in five independent experiments were used to generate cell proliferation curves.

Scratch migration assay
-----------------------

A498 and CAKI-2 cell monolayers were transfected with negative-control or eIF3b-targeting siRNA for 48 h, scratched with a 100-µL pipette tip, washed twice with phosphate buffer saline (PBS) to remove detached cells, and incubated further in growth medium without FBS to ensure that the cells did not proliferate extensively and that most distributional changes would reflect cell migration. Wound closure (reflected by cell migration into the initially cell-free scratch area) was measured after 0, 8, 16, and 24 h. All experiments were performed in triplicate.

Transwell migration and invasion assays
---------------------------------------

We used Corning Matrigel® Invasion Chambers (8-μM pore size; BD Biosciences, USA). Cells (5.0 × 10^4^/500 μL serum-starved medium) were added to the upper chambers and complete medium to the bottom wells. After 16 h, 5% (w/v) glutaraldehyde was added to both chambers, followed by 0.1% (w/v) crystal violet. The upper faces of the filters were then wiped with cotton swabs. Images of five 200× fields were captured from each membrane and the numbers of invading cells were counted. In the invasion assay, the upper faces of the membranes were coated with 60-µL amounts of a 1:6 (w/v) dilution of Matrigel®. After incubation at 37°C for 1 h, the chambers were used in the invasion assay. The subsequent steps were the same as described above.

Cell cycle analysis and measurement of apoptosis
------------------------------------------------

Seventy-two hours after transfection, cells were harvested and subjected to flow cytometry, for evaluation of cell cycle status using a Bestbio (China) kit (catalog no. BB-4104-50T) and measurement of apoptosis status using a BD (USA) kit (catalog no. 556547). We employed a BD FACSCalibur^TM^ cytometer. Cell cycle status was evaluated using Modifit LT 4.1 software (Verity Software House, USA) and apoptosis status analyzed with the aid of FCS version V3 software (De Novo, USA).

Lentivirus transfection
-----------------------

A lentivirus-mediated eIF3b siRNA-delivery system was constructed by Genechem, China. The GV248 vector contained the elements hU6-MCS-ubiquitin-EGFP-IRES-puromycin; the clone was transfected with the aid of Enhanced Infection Solution (Genechem, China) with 5 µg/mL polybrene. After 12 h of incubation, the transfection medium were changed to normal culture medium with 10% (v/v) FBS.

Colony formation
----------------

Lentivirus-transfected cells were seeded at 100 cells/well into 6-well culture dishes, incubated for 8 d, and fixed and stained with 0.1% (w/v) crystal violet. Colonies containing \> 50 cells were counted. All experiments were performed in triplicate.

Subcutaneous xenografts in nude mice
------------------------------------

Tumor xenografts were established by injecting 5 × 10^6^ A498-LV-eIF3b-RNAi cells in 200-µL amounts of PBS into the right flanks of 6-week-old female BALB/c nude mice (n = 5 per group; Biomedical Research Institution of Nanjing University, China). The two greatest tumor diameters were measured every 4 days with calipers and tumor volumes were calculated as V = L × l^2^× 0.5, where L and l represent the larger and smaller diameters. All animal care followed our institutional guidelines. Mice were sacrificed before the volume of the largest tumor attained 1,000 mm^3^. All animal experiments followed the dictates of the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the work was approved by the Committee on the Use and Care of Animals of Shandong University.

Statistical Analysis
--------------------

Statistical analyses were performed with the aid of SPSS version 20 (IBM, USA) and GraphPad Prism® version 5.01 (GraphPad Software, USA). The immunohistochemically measured eIF3b levels and the clinicopathological parameters were compared using chi-squared and Fisher\'s exact tests. Kaplan-Meier analysis followed by log-rank testing was employed in the univariate analysis. Multivariate analyses were performed using Cox\'s proportional hazards regression model. A p-value \< 0.05 was considered to indicate statistical significance. Migration and invasion levels were compared using the Student\'s *t*-test. Real-time PCR data were compared with the aid of the Mann-Whitney U test.

Results
=======

Patient characteristics
-----------------------

The 82 patients with ccRCC had a mean age of 57 years and included 55 males (66.7%) and 27 females (33.3%). Twenty patients (24.7%) died during the follow-up period. The estimated 5-year overall survival (OS) was 84.1%. The numbers of patients with TNM grades I, II, III, and IV were 64, 7, 7, and 4, respectively. The numbers of patients with Fuhrman nuclear grades 1, 2, 3, and 4 were 7, 25, 28, and 22, respectively. The median follow-up time was 76 months. Table [1](#T1){ref-type="table"} lists the details.

EIF3b expression and association thereof with clinicopathological variables
---------------------------------------------------------------------------

The cytoplasm and nuclei of both cancer and renal tubular cells stained positively for eIF3b (Figure [1](#F1){ref-type="fig"}). In tumors, the staining level correlated with the Fuhrman nuclear grade (p = 0.044; Table [1](#T1){ref-type="table"}). Notably, the eIF3b expression levels in ANK tissues were much higher than those in tumors. All ANK tissues (n = 82) stained positively; 30 exhibited low expression (+, ++) and 52 exhibited high expression (+++) (Table [2](#T2){ref-type="table"}). eIF3b expression in ANK tissue was associated with the tumor T stage (p = 0.046; Table [2](#T2){ref-type="table"}). eIF3b downregulation in tumor tissue was also confirmed by qRT-PCR of fresh samples (Figure [2](#F2){ref-type="fig"}A). eIF3b expression was significantly higher in NK tissue (p = 0.038) and ANK tissue (p = 0.04) than in tumors. Additionally, eIF3b was expressed at a significantly higher level in metastatic than in non-metastatic tumors (p = 0.0262), indicating that eIF3b contributes to tumor progression.

The tumor eIF3b expression level was independently prognostic for patients with ccRCC
-------------------------------------------------------------------------------------

Patients with tumors positive for eIF3b (+, ++, +++) (p = 0.002; Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}B), high TNM grades (p = 0.001; Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}C), advanced Fuhrman nuclear grades (p = 0.036; Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}D), and low-level eIF3b expression in ANK tissue (p = 0.047; Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}E) had significantly poorer prognoses. Furthermore, when tumor eIF3b expression was divided into four categories (-, +, ++, +++), the correlation analysis showed that such expression was significantly (positively) associated with the nuclear grade (Figure [2](#F2){ref-type="fig"}F). Kaplan-Meier analysis indicated that the greater the level of tumor eIF3b expression, the poorer the OS (p = 0.008; Figure [2](#F2){ref-type="fig"}G). If we divided all the patients, according to eIF3b expression, into four groups including tumor (-) & adjacent (+ or ++), tumor (-) & adjacent (+++), tumor (+) & adjacent (+ or ++) and tumor (+) & adjacent (+++) (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). Kaplan-Meier analysis indicated that patients with tumor eIF3b (+) and ANK (+ or ++) experienced worse OS compared to the other three groups. (Figure [2](#F2){ref-type="fig"}H). The multivariate analysis showed that the TNM grade (p = 0.023; Table [3](#T3){ref-type="table"}) and the eIF3b tumor expression level (p = 0.019; Table [3](#T3){ref-type="table"}) were independently prognostic for patients with ccRCC.

Depletion of eIF3b inhibited cell proliferation, migration, and invasion
------------------------------------------------------------------------

A498 and CAKI-2 cells (which express high levels of eIF3b) were used to conduct *in vitro* experiments (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}A). Cell proliferation was significantly inhibited after eIF3b knockdown (Figure [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B; Supplementary Figure [1](#SM1){ref-type="supplementary-material"}B). Additionally, cell colony numbers fell after eIF3b depletion (Figure [3](#F3){ref-type="fig"}C). Furthermore, migration capacity was significantly impaired after eIF3b knockdown (Figure [3](#F3){ref-type="fig"}D). In the transwell assay, eIF3b depletion reduced the number of cells traversing the membrane (compared with control cells) (Figure [3](#F3){ref-type="fig"}E). Therefore, eIF3b depletion impaired both cell migration and invasion. Notably, eIF3b depletion caused the cells to become smaller and rounded, suggesting that both migration and adhesion were impaired compared with control cells (Figure [3](#F3){ref-type="fig"}F).

eIF3b depletion triggered G1/S and G2/M arrest
----------------------------------------------

We explored the effects of eIF3b depletion on the cell cycle. The proportion of cells in S-phase was lower in eIF3b-depleted cells (Figure [4](#F4){ref-type="fig"}A) and the proportion in the G1 phase was higher (Figure [4](#F4){ref-type="fig"}A) than that in the negative control. Western blotting showed that the G1/S arrest was caused by eIF3b depletion (Figure [4](#F4){ref-type="fig"}B). During the G1/S transition, cyclins D and E combine with cyclin-dependent kinases (CDK) to form the cyclin/CDK complexes required for the transition. The complexes phosphorylate the retinoblastoma protein (Rb), releasing the E2F transcription factor that activates expression of G1/S progression genes. We found that the levels of both cyclins D and E decreased after eIF3b knockdown. Cyclins D and E, Rb, and the inactivated form of Rb (p-Rb) were downregulated after eIF3b knockdown. In addition, the levels of p27 Kip1 and p21 Cip1, inhibitors of the cyclin/CDK complexes, significantly increased after eIF3b knockdown. Interestingly, Western blotting of G2/M-related proteins indicated that the G2/M transition was also inhibited after eIF3b knockdown (Figure [4](#F4){ref-type="fig"}C). Cyclin A, which accumulates steadily during the G2 phase and is abruptly destroyed at mitosis, was upregulated after eIF3b depletion. Cyclin B is required for the G2/M transition; we found that the cyclin B level fell. Also, the levels of Myt1 and Wee1 increased after eIF3b depletion; these proteins inhibit cell entry into mitosis. The observed decrease in histone H3 phosphorylation indicated that chromosome condensation was reduced by eIF3b depletion; fewer cells were in the mitotic phase.

Knockdown of eIF3b promoted apoptosis of renal cancer cells
-----------------------------------------------------------

As eIF3b depletion reduced cell proliferation *in vitro*, we explored whether apoptosis was involved. The levels of apoptosis increased slightly after eIF3b depletion (Figure [4](#F4){ref-type="fig"}D). Further analysis (Figure [4](#F4){ref-type="fig"}E) showed that, after eIF3b knockdown, the pro-apoptotic factors Bax, caspase-3, and the activated form thereof (cleaved caspase-3) were all upregulated and the pro-survival factor Bcl-2 was downregulated. More importantly, cleavage of poly-ADP-ribose polymerase (c-PARP), a marker of apoptosis, was also increased. Therefore, apoptosis increased after eIF3b knockdown. However, interestingly, knockdown reduced the level of cleaved caspase-12, which is required for endoplasmic reticulum-stress-induced apoptosis (Figure [4](#F4){ref-type="fig"}E).

Impairment of the β-catenin pathway inhibited the epithelial-to-mesenchymal transition (EMT) after eIF3b depletion
------------------------------------------------------------------------------------------------------------------

The EMT is a key event in tumor invasion and metastasis, including RCC [@B23]. We found that the epithelial marker E-cadherin was upregulated and the levels of repressors thereof (Slug and Snail) were downregulated after eIF3b depletion. Additionally, the mesenchymal markers N-cadherin and vimentin were downregulated. Therefore, the EMT was inhibited by eIF3b depletion (Figure [5](#F5){ref-type="fig"}A). The β-catenin pathway is involved in regulation of the EMT [@B24]. We found that β-catenin expression was significantly downregulated after eIF3b depletion (Figure [5](#F5){ref-type="fig"}A). The level of cyclin D1 (Figure [4](#F4){ref-type="fig"}B), a target of β-catenin, was also downregulated after eIF3b depletion. Together, our data showed that eIF3b depletion inactivated the β-catenin pathway and inhibited the EMT of ccRCC.

The Akt pathway was impaired after eIF3b depletion
--------------------------------------------------

The serine/threonine kinase Akt (also termed protein kinase B or PKB) has attracted a great deal of attention because Akt plays critical roles in the regulation of many cellular functions including metabolism, growth, proliferation, survival, transcription, and protein synthesis [@B25]-[@B29]. We found that eIF3b depletion was not associated with any significant change in Akt levels; however, the level of the activated form, p-Akt, fell in parallel with the extent of eIF3b depletion, indicating that the Akt signaling pathway was involved in such depletion.

The significant morphological changes in cells after eIF3b depletion (Figure [3](#F3){ref-type="fig"}F) suggested that the integrin pathway might be affected; integrin links the extracellular matrix to the intracellular cytoskeleton to facilitate focal adhesion [@B30]. After eIF3b knockdown, the levels of integrins α2 and α5 fell significantly, as did the level of the upstream phosphorylated Focal adhesion kinase (p-FAK) protein, suggesting that integrin/FAK/Akt signaling was inhibited (Figure [5](#F5){ref-type="fig"}B).

Akt plays a critical role in cell growth by directly phosphorylating the mechanistic target of rapamycin (mTOR) [@B31]. We found that p-mTOR was downregulated after eIF3b knockdown, indicating that the Akt/mTOR pathway was impaired (Figure [5](#F5){ref-type="fig"}B). Furthermore, the observed downregulation of HIF-1α, HIF-2α, and p-NF-κB after eIF3b depletion may indicate that the Akt/mTOR/HIF [@B29] and Akt/mTOR/NF-κB [@B28] pathways were also downregulated (Figure [5](#F5){ref-type="fig"}B), compromising cell proliferation and inducing apoptosis. The observed reduction in HIF-1α and HIF-2α levels suggested that the cells would be less able to endure hypoxia, reducing cell survival. Vascular Endothelial Growth Factor Receptor (VEGFR), which is often targeted in patients with RCC, was also downregulated (Figure [5](#F5){ref-type="fig"}B).

Akt promotes cell survival by inhibiting apoptosis via phosphorylation (inactivation) of several proteins [@B32], including Bcl-2 and Bax (Figure [4](#F4){ref-type="fig"}E). Apart from the roles played in survival and apoptosis, the Akt pathway is also involved in cell cycle regulation, preventing GSK-3β-mediated phosphorylation and degradation of cyclin D1 [@B25], [@B33] and negatively regulating the actions of p27 Kip1 [@B26] and p21 Waf1/Cip1 [@B27]. We found that GSk-3β and cyclin D1 were upregulated and p27 Kip1 and p21 Cip1 were downregulated after eIF3b depletion (Figures [4](#F4){ref-type="fig"}B and [5](#F5){ref-type="fig"}B), indicating that the Akt/GSK-3β pathway was involved in cell cycle regulation of A498 and CAKI-2 cells.

EIF3b depletion inhibited the growth of subcutaneous xenografts in mice
-----------------------------------------------------------------------

To further investigate the roles played by eIF3b and to validate eIF3b as a potential therapeutic target *in vivo*, we injected nude mice with A498 cells transfected with the eIF3b-RNAi-containing lentivirus (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}C). Control cells yielded could grow into significantly larger tumors than did eIF3b-RNAi-lentivirus transfected cells (p \< 0.001; Figure [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B). Therefore, eIF3b knockdown inhibited the growth of subcutaneous xenografts in mice. And about 2 months after transfection, cells transfected with eIF3b-RNAi lentivirus was found in a worse situation with more cell debris than control cells (Figure [6](#F6){ref-type="fig"}C).

Discussion
==========

Recent studies have shown that certain components of several eIFs can serve as potential prognostic biomarkers and therapeutic targets for several cancers. The relevant components include eIF4E, eIF4A, eIF2α, eIF3a, eIF4B, eIF4F, and eIF5A [@B4], [@B34]-[@B42]. However, the role of eIF3b in RCC was previously unclear.

We found that higher-level tumor eIF3b expression was associated with a more aggressive phenotype and, more importantly, that the tumor eIF3b expression level was independently prognostic of ccRCC progression. This carcinogenic role of eIF3b was confirmed by *in vitro* experiment that eIF3b knockdown inhibited tumor cell proliferation, migration, and invasion.

We then showed that eIF3b depletion inhibited cell proliferation by compromising the cell cycle and inducing cell apoptosis. The G1/S arrest after eIF3b depletion has also been noted in bladder cancer [@B20], glioblastoma [@B12], and esophageal squamous carcinoma [@B19]. Wang *et al.* found that reduction in overall protein synthesis by eIF3b depletion lead to the smaller size of cells which cannot pass the major size regulatory "R or restriction point" checkpoint, which is also a G1/S arrest reason [@B20]. We also found, *in vitro*, that the G2/M transition was impaired after eIF3b depletion. However, such impairment may be weak; it was not apparent on flow cytometry. In addition, apoptosis increased after eIF3b depletion. Similar pro-apoptotic effects have been reported in colon cancer [@B13], glioblastoma [@B12], and esophageal squamous carcinoma [@B19]. Interestingly, ER-stress-induced apoptosis seemed to be downregulated after eIF3b depletion. However, the overall effect of eIF3b depletion was pro-apoptotic in ccRCC.

Cell proliferation, migration, and invasion were reduced after eIF3b knockdown. The EMT is a key event in renal tumor invasion and metastasis [@B23]. We found that the EMT was impaired after eIF3b knockdown, which was characterized by upregulation of E-cadherin and downregulation of N-cadherin, vimentin, and repressors of E-cadherin. We also found that inhibition of the β-catenin pathway contributed to the EMT impairment after eIF3b depletion.

eIF3b knockdown inhibited many activities of the Akt pathway network in RCC cells, including the integrin/FAK/Akt, Akt/mTOR/HIF/VEGF, Akt/mTOR/NF-κB, Akt/Bcl-2/Bax, and Akt/GSK-3β pathways. Inhibition of the integrin/FAK/Akt pathway changed the cellular morphology and impaired adhesion. Inhibition of the Akt/mTOR/HIF/VEGF and Akt/mTOR/NF-κB pathways compromised cell proliferation and increased apoptosis. Akt pathway inhibition also induced apoptosis via downregulation of Bcl-2 and Bax. Inhibition of the Akt/GSK-3β pathway contributed to G1/S arrest.

Dysregulation of protein synthesis has been implicated in the impaired oncogenicity after eIF3b depletion. The inherent "translatability" of different mRNAs varies widely [@B43], [@B44]. "Weak" mRNAs encoding proteins involved in cell proliferation are translated after activation of the protein synthesis apparatus [@B14], [@B45]. Not all mRNAs are translated to an equal extent, as we also found. mRNA encoding oncogenic proteins seem to be poor competitors (compared with other mRNAs) of the translational complex. Therefore, after eIF3b depletion, the translation of oncogenic proteins in the EMT and Akt signaling pathways is significantly inhibited. In other words, these pathways are stimulated when the level of overall protein synthesis is high (e.g., in tumors expressing high levels of eIF3b). Activation of protein synthesis triggers overproduction of oncogenic proteins and rapid cell growth; downregulation of protein synthesis preferentially impairs the expression of oncogenic proteins, restoring controls on proliferation. This explains why patients with high levels of tumor eIF3b experience poor OS.

Many clinical analyses and *in vitro* experiments have indicated that tumor eIF3b plays a role in tumor progression. EIF3b is highly expressed in certain tumors [@B12], [@B13], [@B19], [@B20]. It is thus of considerable interest that we found eIF3b to be downregulated in ccRCC, as evident both immunohistochemically and upon qRT-PCR. Furthermore, we found that high-level eIF3b expression in ANK tissue correlated with longer OS and a less aggressive tumor phenotype; eIF3b thus seems to play a totally different role in normal kidney cells. It is well-known that, transforming growth factor beta (TGF-β) plays different roles in cancer initiation and progression, both suppressing and promoting such progression [@B46]. We suggest that eIF3b may, like TGF-β, play different roles in kidney cancer. In tumor cells, eIF3b contributes to tumor progression but in non-tumor cells, it plays a protective role in patients with ccRCC. Further *in vitro* research and study of a larger sample of tumor and normal tissues are required.

eIF3b knockdown inhibited the growth of subcutaneous tumors in mice, confirming eIF3b as a potential therapeutic target for patients with ccRCC. As the high expression in normal kidney tissues, the impact on normal kidney tissues cannot be ignored and it is difficult to design specific therapeutic agents to target this protein. However, after we uncover the role of eIF3b in normal kidney in the future, it is possible to apply this protein to the clinic. Nowadays, RNA-based therapeutics, such as small-interfering (siRNA), microRNAs, antisense oligonucleotides (ASOs), CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes to treat cancers [@B47]. Besides, recent advances has helped to overcome the lipid bilayer to deliver the RNA into cells cytoplasm and nucleus and enabled RNA-based therapeutics directed to other cancer targets to progress into clinical trials for cancer [@B48], [@B49]. There is also research showing that intratumoral administration of ASOs can antagonize pancreatic cancer growth *in vivo* [@B50], which points out a promising way of for clinic application research of RNA-based therapeutics targeting eIF3b.

There were certain limitations to our study. We failed to explore the reason why eIF3b expression is higher in ANK than that in tumors. Regulation of involved protein in cancer progression is very complicated. Methylation is probably one of them. A research on breast cancer showed that the status of methylation of genes in tumor is not exactly the same as the adjacent normal [@B51]. The difference of methylation of eIF3b gene may contribute to the discrepancy of eIF3b protein expression in tumor compared to adjacent tissue. So more work need to be done to uncover the methylation and gene status of ANK and NK tissue.

Together, our results suggest that high-level expression of eIF3b in cancer cells may be essential for expression of the transformed phenotype, and that tumor eIF3b expression is independently prognostic for patients with ccRCC. Furthermore, *in vitro* eIF3b knockdown effectively impaired the Akt pathway, inhibiting cell proliferation by disrupting the cell cycle, and triggering apoptosis. eIF3b depletion also impaired the EMT, suppressing cell migration and invasion. More importantly, the *in vivo* work showed that eIF3b may be a useful therapeutic target for patients with ccRCC. More work is needed to understand what role eIF3b plays in non-tumor kidney cell and how eIF3b interacts with other eIFs in terms of cancer development.
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![A: qRT-PCR of fresh samples revealed that eIF3b mRNA expression was downregulated in cancer tissues (p = 0.0137, n = 20) and was significantly greater in metastatic than in non-metastatic tumors (p = 0.0262). B: Kaplan-Meier analysis of the effect of the tumor eIF3b level on OS. C: Kaplan-Meier analysis and log-rank testing of the effect of the TNM grade on OS. D: Kaplan-Meier analysis and log-rank testing of the effect of the nuclear Fuhrman grade on OS. E: Kaplan-Meier analysis of the effect of the ANK eIF3b level on OS. F: The tumor eIF3b expression correlated with the nuclear grade. G: Kaplan-Meier analysis of the effect of the eIF3b level (four categories) on OS. H: Kaplan-Meier analysis of eIF3b level in both tumor and adjacent normal (four categories) on OS.](jcav08p3049g002){#F2}

![eIF3b knockdown inhibited cell proliferation, migration, and invasion. A-B: eIF3b knockdown inhibited the proliferation of A498 (A) and CAKI-2 (B) cells. C: EIF3b-depleted cells formed fewer colonies. D: The scratch migration assay indicated that A498 and CAKI-2 migration was inhibited after eIF3b knockdown. E: The transwell assay also revealed that migration was impaired (cell numbers, eIF3b siRNA vs. negative control: A498 cells, 45.3 ± 4.9 vs. 100.3 ± 7.3 \[p \< 0.01\]; CAKI-2 cells, 71.0 ± 6.1 vs. 125.3 ± 7.8 \[p \< 0.01\]), as was the invasive capacity (cell numbers, eIF3b siRNA vs. negative control: A498 cells, 13.3 ± 3.8 vs. 39.7 ± 6.2 \[p \< 0.05\]; CAKI-2 cells, 35.0 ± 6.1 vs. 73.3 ± 8.1 \[p \< 0.05\]), upon eIF3b depletion. F: Changes in cellular morphology after eIF3b depletion.](jcav08p3049g003){#F3}

![Changes in the cell cycle and apoptosis after eIF3b depletion. A: Cell cycle flow cytometry identified G1/S arrest (with more G1-phase cells and fewer S-phase cells). B: Western blotting of G1/S-related proteins verified the G1/S arrest. C: Changes in G2/M-related protein levels indicated that G2/S arrest was also present after eIF3b depletion. D: Cell apoptosis flow cytometry revealed that apoptosis increased after eIF3b depletion. E: Western blotting confirmed the apoptotic changes.](jcav08p3049g004){#F4}

![Pathways affected by eIF3b knockdown. A: eIF3b depletion inhibited EMT progression by inactivating the β-catenin pathway. B: The Akt pathway was inhibited after eIF3b depletion.](jcav08p3049g005){#F5}

![The animal experiment. A: eIF3b knockdown inhibited the growth of subcutaneous RCC xenografts in mice. B: Xenograft samples after 28 d of growth. C: A498 cells transfected with the eIF3b-RNAi lentivirus (left: eIF3b expression was significantly reduced; right: the transfected cells were abnormal in shape with much more cell debris than control cells) (red arrow: cell debris).](jcav08p3049g006){#F6}

###### 

Correlations between tumor eIF3b expression levels and the clinicopathological variables of patients with ccRCC (n = 82)

  Variables                No. of patients   eIF3b expression (tumor)   P value   
  ------------------------ ----------------- -------------------------- --------- -------
  Age                                                                             
  ≥57 years                41                15                         26        0.12
  \<57 years               41                22                         19        
  Gender                                                                          
  Male                     55                25                         30        0.931
  Female                   27                12                         15        
  T stage                                                                         
  T1-2                     74                36                         38        0.067
  T3-4                     8                 1                          7         
  N stage                                                                         
  N0                       78                37                         41        0.123
  N1                       4                 0                          4         
  M stage                                                                         
  M0                       76                36                         40        0.215
  M1                       6                 1                          5         
  TNM grade                                                                       
  I - II                   71                35                         36        0.1
  III - IV                 11                2                          9         
  Furhman nulcear grade                                                           
  1-2                      32                19                         13        0.044
  3-4                      50                18                         32        
  eIF3b expression (ANK)                                                          
  Low expression (+, ++)   30                15                         15        0.5
  High expression (+++)    52                22                         30        

eIF3b, eukaryotic translation initiation factor 3 b; ccRCC , clear cell renal cell carcinoma; ANK, adjacent normal kidney.

###### 

Correlations between the eIF3b expression levels in adjacent normal kidney (ANK) tissues and the clinicopathological variables of patients with ccRCC (n = 82)

  Variables               No. of patients   eIF3b expression (ANK)   P value   
  ----------------------- ----------------- ------------------------ --------- -------
  Age                                                                          
  ≥57 years               41                15                       26        1
  \<57 years              41                15                       26        
  Gender                                                                       
  Male                    55                20                       35        0.953
  Female                  27                10                       17        
  T stage                                                                      
  T1-2                    74                24                       50        0.046
  T3-4                    8                 6                        2         
  N stage                                                                      
  N0                      78                28                       50        0.621
  N1                      4                 2                        2         
  M stage                                                                      
  M0                      76                26                       50        0.185
  M1                      6                 4                        2         
  TNM grade                                                                    
  I - II                  71                23                       48        0.088
  III - IV                11                7                        4         
  Furhman Nulcear grade                                                        
  1-2                     32                9                        23        0.245
  3-4                     50                21                       29        

###### 

Results of the univariate and multivariate analyses

  Variables                   Univariate Analysis   Multivariate Analysis                    
  --------------------------- --------------------- ----------------------- ------- -------- -------
  Age                         0.934                                                          
  Gender                      0.285                                                          
  TNM grading                 0.001                 2.982                   1.166   7.624    0.023
  Furhman Nuclear Grade       0.036                 2.328                   0.771   7.03     0.134
  eIF3b expression In ANK     0.047                 0.542                   0.184   1.597    0.266
  eIF3b expression In tumor   0.002                 4.488                   1.283   15.704   0.019

HR, hazard ratio; CI, confidence interval.
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